Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | DDX3X | O00571 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879825 | 0.72 | CXCR4 (0.70) | CXCR4NTRK1CNR2VNN1KDM4E | |
| SCHEMBL13879823 | 0.72 | CXCR4 (0.60) | CXCR4NTRK1CNR2ACHEKDM4E | |
| SCHEMBL14005210 | 0.71 | CXCR4 (0.48) | CXCR4CNR2MAPTADORA2A | |
| SCHEMBL14005000 | 0.71 | NPC1 (0.45) | DDX3XKDM4EMAPTADORA2A | |
| SCHEMBL13879826 | 0.70 | CXCR4 (1.00) | CXCR4NTRK1CNR2VNN1KDM4E | |
| SCHEMBL14272902 | 0.70 | CXCR4 (0.81) | CXCR4CNR2KDM4EADORA2A | |
| SCHEMBL13879827 | 0.70 | CXCR4 (0.86) | CXCR4NTRK1CNR2KDM4EMAPT | |
| SCHEMBL3382420 | 0.68 | CNR2 (0.60) | NTRK1CNR2 | |
| SCHEMBL76465 | 0.67 | SCD (0.51) | CXCR4 | |
| SCHEMBL12796227 | 0.64 | LRRK2 (0.48) | CXCR4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CXCR4 3/4885NTRK1 1878/4885STAT6 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.